THE RIBONUCLEOTIDE REDUCTASE INHIBITOR (E)-2'-FLUOROMETHYLENE-2'-DEOXYCYTIDINE (MDL-101,731) - A POTENTIAL TOPICAL THERAPY FOR HERPES-SIMPLEX VIRUS-INFECTION

Authors
BRIDGES CG AHMED SP SUNKARA PS MCCARTHY JR TYMS AS
Citation
Cg. Bridges et al., THE RIBONUCLEOTIDE REDUCTASE INHIBITOR (E)-2'-FLUOROMETHYLENE-2'-DEOXYCYTIDINE (MDL-101,731) - A POTENTIAL TOPICAL THERAPY FOR HERPES-SIMPLEX VIRUS-INFECTION, Antiviral research, 27(4), 1995, pp. 325-334
Citations number
24
Categorie Soggetti
Virology
Journal title
Antiviral research → ACNP
ISSN journal
01663542
Volume
27
Issue
4
Year of publication
1995
Pages
325 - 334
Database
ISI
SICI code
0166-3542(1995)27:4<325:TRRI(>2.0.ZU;2-Q
Abstract
The ribonucleotide reductase inhibitor MDL 101,731 was examined for an tiviral activity against herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2) in vitro and in combination with acyclovir in the murine zos teriform model of HSV-1 infection. The in vitro antiviral activity (IC 50) for both serotypes of HSV was similar and in the range 23-98 nM fo r Vero cells. Comparable activities were obtained against acyclovir-re sistant viruses. In the zosteriform model, topical combination therapy of MDL 101,731 with acyclovir (5%:5% w/w) applied 48 h after infectio n was more effective than acyclovir alone and even appeared to promote lesion resolution.